U.S. markets closed

Gain Therapeutics, Inc. (GANX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.9700+0.0100 (+0.25%)
At close: 04:00PM EST
4.1700 +0.20 (+5.04%)
After hours: 04:37PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close3.9600
Bid3.4700 x 1300
Ask5.9700 x 900
Day's Range3.8287 - 4.0550
52 Week Range2.3300 - 6.7000
Avg. Volume38,325
Market Cap47.177M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.2340
Earnings DateMar 22, 2023 - Mar 27, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for GANX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Gain Therapeutics, Inc.
    Daily – Vickers Top Insider Picks for 06/28/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Fair Value
    Economic Moat
    7 months agoArgus Research
View more

    Sidoti's January Micro-Cap Conference

    Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day January Micro-Cap Conference taking place Wednesday and Thursday, January 18-19, 2023.

  • GlobeNewswire

    Gain Therapeutics to Present at Sidoti Small-Cap Virtual Investor Conference

    BETHESDA, Md., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that Matthias Alder, CEO, will present a corporate update at the Sidoti Small-Cap Virtual Investor Conference on Wednesday, January 18 at 2:30 PM ET. A webcast of the presentation

  • Zacks

    Gain Therapeutics, Inc. (GANX) Reports Q3 Loss, Lags Revenue Estimates

    Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of 17.39% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?